Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

58 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Hypersensitivity to the CGRP Inhibitor Monoclonal Antibodies Galcanezumab, Erenumab, and Fremanezumab With Tolerance to Eptinezumab.
Barroso B, Rodrigo-Muñoz JM, Gil-Martínez M, Del Pozo V, Rodríguez-Vico J, Betancor D, Valverde-Monge M, Gómez-López A, Sastre J. Barroso B, et al. Among authors: gil martinez m. J Investig Allergol Clin Immunol. 2024 Oct;34(5):348-349. doi: 10.18176/jiaci.1000. J Investig Allergol Clin Immunol. 2024. PMID: 39441051 Free article. No abstract available.
Single-cell RNA sequencing of human blood eosinophils reveals plasticity and absence of canonical cell subsets.
Rodrigo-Muñoz JM, Naharro-González S, Callejas S, Relaño-Ruperez C, Torroja C, Benguria A, Lorente-Sorolla C, Gil-Martínez M, García de Castro Z, Cañas JA, Valverde-Monge M, Bernaola J, Pinillos-Robles EJ, Betancor D, Fernández-Nieto M, Dopazo A, Sánchez-Cabo F, Sánchez-Pernaute O, Rodríguez-Nieto MJ, Sastre J, Del Pozo V. Rodrigo-Muñoz JM, et al. Among authors: gil martinez m. Allergy. 2024 Jun 27. doi: 10.1111/all.16213. Online ahead of print. Allergy. 2024. PMID: 38934897 No abstract available.
Benralizumab reduces blood basophil percentage and activation in vitro without eliciting degranulation.
Gil-Martínez M, Rodrigo-Muñoz JM, Lorente-Sorolla C, de Castro ZG, Mínguez P, Cañas JA, Valverde-Monge M, Bernaola J, Pinillos-Robles EJ, Betancor D, Fernández-Nieto M, Sastre J, Rodríguez-Nieto MJ, Del Pozo V. Gil-Martínez M, et al. Allergy. 2024 Sep;79(9):2551-2553. doi: 10.1111/all.16190. Epub 2024 Jun 6. Allergy. 2024. PMID: 38841822 No abstract available.
Relationships between Patient-Reported Outcome Measures and Clinical Measures in Naïve Neovascular Age-Related Macular Degeneration Patients Treated with Intravitreal Ranibizumab.
Almuiña-Varela P, García-Quintanilla L, Rodríguez-Cid MJ, Gil-Martínez M, Abraldes MJ, Gómez-Ulla F, Estany-Gestal A, Alcántara-Espinosa JM, Fernández-Rodríguez M, Fernández-Ferreiro A. Almuiña-Varela P, et al. Among authors: gil martinez m. Pharmaceuticals (Basel). 2024 Jan 25;17(2):157. doi: 10.3390/ph17020157. Pharmaceuticals (Basel). 2024. PMID: 38399372 Free PMC article.
The Effect of Systemic Parameters and Baseline Characteristics in Short-Term Response Analysis with Intravitreal Ranibizumab in Treatment-Naive Patients with Neovascular Age-Related Macular Degeneration.
García-Quintanilla L, Almuiña-Varela P, Rodríguez-Cid MJ, Gil-Martínez M, Abraldes MJ, Gómez-Ulla F, González-Barcia M, Mondelo-García C, Estany-Gestal A, Otero-Espinar FJ, Fernández-Rodríguez M, Fernández-Ferreiro A. García-Quintanilla L, et al. Among authors: gil martinez m. Pharmaceutics. 2024 Jan 13;16(1):105. doi: 10.3390/pharmaceutics16010105. Pharmaceutics. 2024. PMID: 38258115 Free PMC article.
58 results